BFNH BioForce Nanosciences Holdings (PK)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * KAISER RICHARD KAISER	2. Issuer Name and Ticker or Trading Symbol BIOFORCE NANOSCIENCES HOLDINGS, INC. [ BFNH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    __X__ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) CFO
(Last)          (First)          (Middle) 3419 VIRGINIA BEACH BLVD, UNIT 252	3. Date of Earliest Transaction (MM/DD/YYYY) 12/4/2020
(Street) VIRGINIA BEACH, VA 23452 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 12/7/2020	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/4/2020		A		3000000 (1)	A	$0.001	5050000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Preferred 'A'	$0.001	12/4/2020		M (1)		500000		12/31/2020	12/31/2040	Common Stock	3000000 (1)	$0.001	0	D

Explanation of Responses:

(1)

On December 4, 2020, BioForce Nanosciences Holdings, Inc. (The "Company" or the "Registrant") issued 3,000,000 shares of its common stock to the reporting individual in exchange for 500,000 shares of its Preferred Series 'A' shares. These shares were issued pursuant to an exemption from registration provided by Section 4(2) of the Securities Act of 1933. The issuance was not a public offering as defined in Section4(2)due to the limited number of persons that received the shares, and the matter of the issuances. In addition, the transferee of the common stock represented that they had the necessary investment intent as required by Section 4(2) and agreed to receive shares containing a legend that states the securities were restricted pursuant to Rule 144 of the Securities Act.

Remarks: This amendment was filed to correct information contained within the footnote #1. The reporting person exchanged 500,000 Preferred 'A' shares for 3,000,000 common shares of the issuer, BioForce Nanosciences Holdings, Inc. The filing corrects the mistake saying reporting person converted 1,500,000 Preferred 'A' shares for 11,000,000 common shares.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
KAISER RICHARD KAISER 3419 VIRGINIA BEACH BLVD, UNIT 252 VIRGINIA BEACH, VA 23452	X	X	CFO

Signatures
/s/ Richard Kaiser		12/7/2020
**Signature of Reporting Person		Date